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Background: Photodynamic therapy (PDT) is a less invasive and effective salvage treatment for local failure after
chemoradiotherapy (CRT) for esophageal cancer, however it causes a high rate of skin phototoxicity and requires
a long sun shade period. Talaporfin sodium is a rapidly cleared photosensitizer that is expected to have less
phototoxicity. This study was undertaken to clarify the optimum laser fluence rate of PDT using talaporfin sodium
and a diode laser for patients with local failure after CRT or radiotherapy (RT) for esophageal cancer.
Methods: This phase I, laser dose escalation study used a fixed dose (40 mg/m2) of intravenous talaporfin sodium
administered 4 to 6 hours before irradiation in patients with local failure limited to T2 after CRT or RT (≥ 50 Gy).
The primary endpoint was to assess the dose limiting toxicity (DLT) of PDT, and the secondary endpoints were
to evaluate the adverse events and toxicity related to PDT. The starting fluence of the 664 nm diode laser was
50 J/cm2, with an escalation plan to 75 J/cm2 and 100 J/cm2.
Results: 9 patients with local failure after CRT or RT for ESCC were enrolled and treated in groups of 3 individuals
to the third fluence level. No DLT was observed at any fluence level. Phototoxicity was not observed, but one
subject had grade 1 fever, three had grade 1 esophageal pain, and 1 had grade 1 dysphagia. Five of 9 patients
(55.6%) achieved a complete response after PDT.
Conclusions: PDT using talaporfin sodium and a diode laser was safe for local failure after RT in patients with
esophageal cancer. The recommended fluence for the following phase II study is 100 J/cm2.
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Chemoradiotherapy (CRT) is one of the curative treat-
ment options for esophageal cancer. However, local fail-
ure without distant metastasis after completion of CRT
occurs in more than 40% of patients and this remains a
major problem to achieve a cure [1]. Although salvage
esophagectomy is generally indicated in such cases, it
carries with it a high morbidity and mortality [2-5]. If* Correspondence: mmuto@kuhp.kyoto-u.ac.jp
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reproduction in any medium, provided the orthe patients with local failure after completion of CRT
have T2 or earlier T-stage residual tumors or for those
without lymph node metastasis, salvage esophagectomy
has curative potential [2-5]. Onozawa et al. reported that
regional nodal failure within the field of elective lymph
node irradiation was rare in patients achieving a
complete response (CR) after CRT (1%; 95% confidence
interval [CI], 0%–5%) for esophageal squamous cell car-
cinoma (ESCC) [6]. These data might indicate that if
both lymph node and distant metastasis were controlled
by CRT, local salvage treatment that targeted only the
primary site could be a minimally invasive curative treat-
ment option in carefully selected patients.
To develop such a treatment option for local failure,
we have introduced photodynamic therapy (PDT) as ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phase II study of salvage PDT for local residual T1
tumors after CRT [9]. In this study, 76% (19/25) of the
patients could achieve CR and suffered only modest
rates of adverse events and complications. These data
suggest salvage PDT could be a curative treatment
option for patients with local failure after CRT.
However, first generation PDT using porfimer sodium
(Photofrin Injection, Pfizer Japan Inc., Tokyo, Japan) has
some problems such as a high risk of skin phototoxicity
requiring a long sun shade period (4–6 weeks), and the
need for a large and expensive excimer dye laser system.
In contrast, second generation PDT using talaporfin
sodium (Laserphyrin for Injection, Meiji Seika Pharma
Co., Ltd., Tokyo, Japan) is featured as possessing a more
rapid clearance from the skin and a longer absorption
band (664 nm) compared with porfimer sodium. It is
also theoretically expected to have a lower rate of photo-
toxicity with a shorter sun shade period and be more
effective in deeper layers of tissue. Furthermore, the diode
laser system (PD laser, Panasonic Healthcare Co., Ltd.,
Ehime, Japan) that emits 664 nm laser light and excites
the talaporfin sodium is a much smaller system compared
with the excimer dye laser system. In a clinical trial for
early lung cancer treatment, PDT using talaporfin sodium
demonstrated a high response rate (95%), similar to PDT
using porfimer sodium, and modest skin photosensitivity
with a 2 week sun shade period [10]. However, PDT using
talaporfin sodium and diode laser is approved only for
early lung cancer in Japan, and its safety and efficacy have
not been clinically evaluated for other cancers.
The aim of this phase I study was to clarify the
optimum laser irradiation fluence rate, and to evaluate
the safety of PDT using talaporfin sodium and diode
laser for patients with local failure after CRT or radio-
therapy (RT) for esophageal cancer.
Methods
This study was a multi-institutional open label phase I
laser dose escalation study with a fixed dose of talaporfin
sodium for patients with local failure after CRT or
RT for ESCC. The study protocol was approved by
the institutional review board of all participating institu-
tions. This study was conducted in accordance with the
Ethical Guideline for Clinical Research by the Ministry
of Health, Labour and Welfare and the Declaration of
Helsinki. The study was also registered with the Uni-
versity Hospital Medical Information Network (UMIN)
Clinical Trials Registry, and the identification number
is UMIN000003970.
Patients
The eligibility criteria of this study were as follows: 1)
local failure after CRT or RT(≥ 50 Gy) for esophagealcancer; 2) refusal of salvage esophagectomy or lack of
tolerability for salvage esophagectomy; 3) local failed
lesions limited within the muscularis propria (T2);
4) local failed lesions that were not involved in the cer-
vical esophagus, 5) longitudinal lesion length of shorter
than 3 cm and less than one half the circumference of
the lumen; 6) no more than 2 failure lesions; 7) enroll-
ments of patients with lymph node or distant metastasis
were accepted, except for those with indication for
systemic chemotherapy 8) local failure lesions which
meet at least one of the following criteria; a) histologi-
cally proven carcinoma by biopsy specimen, b) emerged
ulceration in the lesions, c) enlarged submucosal tumor
like protrusion in the lesion, d) presence of heteroechoic
solid component with endoscopic ultrasound (EUS)
observation, 9) age ≥ 20, 10) Eastern Cooperative Oncol-
ogy Group performance status≤ 2; 11) adequate bone
marrow function (white blood cell count ≥2000/mm3
and≤ 12,000/mm3, hemoglobin >8.0 g/dL, platelet count
≥75,000/mm3), renal function (serum creatinine level
≤ 2.0 mg/dL), and liver function (serum total bilirubin
level ≤ 2.0 mg/dL, both alanine aminotransferase and
aspartate aminotransferase ≤ 100 IU/L); and 12) provision
of written informed consent.
The exclusion criteria were 1) significant cardiovas-
cular diseases (uncontrolled hypertension, myocardial
infarction, unstable angina, congestive heart failure),
uncontrolled diabetes mellitus, or severe liver cirrhosis;
2) systemic infection requiring antibiotics; 3) inability
to obey the sun shade restrictions; 4) additional PDT
just after salvage endoscopic mucosal resection or endo-
scopic submucosal dissection for local failures; 5) base-
line lesions before CRT or RT judged to involve the
aorta; 6) porphyria; 7) preexisting of sun photosensitiv-
ity; 8) previous treatment with PDT using talaporfin
sodium, or treatment with PDT using porfimer sodium
at least 3 months before enrollment; 9) pregnant or
nursed women, or unwillingness to use of contraception;
and 10) judged by investigator that enrollment was
inappropriate for the patient.
Study design
In the present study, the dose of talaporfin sodium was
the same as that used for lung cancer, because the safety
profile of the 40 mg/m2 dose was already clarified in the
PDT regimen for lung cancer. Therefore, we planned
this laser fluence escalation study to find the optimum
fluence level of diode laser treatment for local failure
after CRT or RT for esophageal cancer. The primary
endpoint of this study was to assess the dose limiting
toxicity (DLT) related with PDT at each level. The sec-
ondary endpoints were to evaluate the adverse events
and toxicity related to PDT. The starting fluence of the
diode laser was 50 J/cm2 (level 1), with the escalation
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100 J/cm2 (level 3). The starting fluence of 50 J/cm2 was
chosen based on results of a pre-clinical study using
canine esophagus model [11]. A minimum of 3 patients
were assessed for toxicity at each level. If a DLT was not
observed within 28 days after laser irradiation, then the
level was raised. If a DLT was observed in one of the
3 patients, an additional 3 patients were treated at the
same fluence level. The maximam tolerated dose (MTD)
was defined at each level when DLT was observed in
2 or more of the 3 patients, or 3 or more of the two 3
patient groups that were treated at the same fluence
level. The recommended dose (RD) for further study in
phase II was defined as just below the level of the MTD.
If the DLT was not observed in the level, then level 3
(100 J/cm2) was defined as the RD for the phase II study.
Staging
In this study, clinical stage was determined according to
the TNM classification of the International Union
Against Cancer 6th edition [12] and the Japanese Classi-
fication of Esophageal Cancer, 10th edition, revised ver-
sion [13]. Clinical T stage was evaluated by endoscopy,
EUS, and computed tomography (CT) of the chest. Clin-
ical N and M stages were evaluated by EUS and CT of
the neck, chest, and abdomen.
Treatment and surveillance
All PDT procedures were performed in an inpatient set-
ting. One hundred milligrams of talaporfin sodium were
dissolved in 4 mL of saline, and a 40 mg/m2 dose was
slowly injected intravenously. Four to 6 hours after
administration of talaporfin sodium, the local failure
lesion was irradiated with diode laser at a 664 nm wave-
length. The diode laser light was delivered via a straight
type fiber without any balloon or light diffuser through
the operative channel of the scope. A plastic attachment
was fitted to the tip of the scope to keep it facing the
lesion and to maintain the distance between the tip of
the straight type fiber and the surface of the lesion dur-
ing the procedure. If the lesions were larger than 1 cm2,
multiple treatment fields were overlapped to cover the
entire lesion. In this phase I study, the starting fluence
was 50 J/cm2 (level 1), with a fixed fluence rate of
150 mW/cm2. If the post laser treatment change (e.g.
ischemic change of mucosa) by endoscopic observation
was suspected to be insufficient, additional laser irradi-
ation was performed on the next day as a second session.
Before enrollment, patients were evaluated with a
physical examination, performance status, dysphagia
score [14] assessment, complete blood count, blood
chemistry, electrocardiogram, and a chest-X ray study.
After patient enrollment, adverse events were observed
and graded until 28 days after laser irradiation. Patientswere assessed through physical examinations, measure-
ments of hematological and biochemical variables in the
blood, chest X-ray studies, and endoscopic examinations,
at least once a week until 28 days after PDT. All patients
were instructed to avoid direct exposure to sunlight for
2 weeks after the injection of talaporfin sodium to pro-
tect them from skin photosensitization. Patients were
allowed to discharge 2 weeks after laser irradiation if
there were no complications related to PDT. Adverse
events and toxicity were graded according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE),
version 4.0 [15].
DLT was defined as follows; 1) pain that requires
administration of opioid analgesics for relief and persists
for 4 days or more; 2) grade 2 or higher fever that per-
sists 4 days or more, in spite of antipyretic administra-
tion; 3) grade 3 or higher esophageal fistula without any
evidence of disease progression; 4) grade 3 or higher
esophageal stenosis without any evidence of disease pro-
gression; 5) grade 3 or higher esophageal hemorrhage
without any evidence of disease progression, 6) grade 4
or higher non-hematological toxicity.
Efficacy
Treatment efficacy and toxicity at the primary site were
evaluated by endoscopy every week for the first 4 weeks
after PDT, and every 2 weeks thereafter until the efficacy
was confirmed. The clinical criteria of CR at the primary
site after PDT were as follows: 1) residual lesion not
observed; 2) disappearance of post PDT ulceration and
confirmation of the scar formation; and 3) histological
confirmation of the absence of cancer cells by biopsy. In
addition, when the ulceration or erosion was not cured
within 6 months after PDT, but the biopsy specimen did
not continuously reveal residual cancer cells, treatment
efficacy was assessed as uncertain CR and they were
evaluated as a CR case.
CT was used to evaluate distant organ or lymph node
metastasis every 3 months after PDT. In this study,
lymph node metastasis was diagnosed clinically if the
lymph node was larger than 10 mm in diameter on CT,
and distant metastasis was diagnosed if the emergent
metastatic lesion was confirmed with CT.
Results
Patients characteristics
Between October 2010 to May 2011, a total of 9 patients
with local failure after CRT or RT for ESCC were en-
rolled and treated in groups of 3 individuals using up to
the third fluence level. Baseline patient and lesion char-
acteristics before CRT or RT are shown in Table 1. All of
the patients were male, and their median age was
72 years old (range: 58–83). The tumor location was the
upper esophagus in one patient, middle esophagus in
Table 1 Baseline patient and lesion characteristics
before RT
Age (y) Gender clinical
stage
histology Location
Level 1 (50 J/cm2)
No.1 74 Male T3N1M1b SCC Middle
No.2 83 Male T3N0M0 SCC Middle
No.3 72 Male T2N0M0 SCC Middle
Level 2 (75 J/cm2)
No.4 58 Male T3N1M0 SCC Middle
No.5 81 Male T1N0M0 SCC Lower
No.6 67 Male T1N0M0 SCC Middle
Level 3 (100 J/cm2)
No.7 77 Male T1N0M0 SCC Upper
No.8 66 Male T2N1M0 SCC Lower
No.9 65 Male T1N0M0 SCC Lower
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line clinical stages before CRT or RT were: stage I in
four, stage II in three, stage III in one, and stage IVb in
one patient. The initial T stage was T1 in 4 patients, T2
in 2 patients, and T3 in 3 patients. Patient and lesion
characteristics before PDT are shown in Table 2. Seven
of the 9 patients were treated with CRT, and the other
two were treated with RT alone. The irradiation dose
for the patients was 60 Gy in 7 patients, 70 Gy in one
patient, and 50.4 Gy in one patient, respectively. The
majority of their chemotherapeutic regimen was cis-
platin plus continuous infusion of fluorouracil. Their
failure patterns were recurrence after achieving a CR
with CRT in 7 patients, and residual tumors just after
CRT in 2 patients. All local failure lesions enrolled in
this study were histologically proven solitary lesion
within the radiation field. The median tumor length was
1.0 cm (range: 0.8-3.0 cm), and the circumference of the
lumen was 7 patients in< 1/4, and 2 patients in 1/4-1/2.
The T stage of the recurrent lesion was T1 in 6 patients,
and T2 in 3 patients. None of them had clinical lymph
node or distant metastasis on CT evaluation before PDT.
Toxicity
All 9 patients received administration of talaporfin
sodium and diode laser irradiation, therefore they were
assessable for DLT. No dermatological adverse events
related to talaporfin sodium, such as allergic reaction or
photosensitivity, were not observed in any patients. DLT
was not observed in any patients at any level of treat-
ments. The hematological and non-hematological toxici-
ties in this study are summarized in Table 3. The
hematological toxicity related to PDT was not observed
in all patients, and when present, the non-hematological
toxicity was generally mild and graded 1 as follows; 1
patient (11%) with grade 1 fever, 3 patients (33%) withgrade 1 esophageal pain, and 1 patient (11%) with
grade 1 dysphagia.
Efficacy
The details of the procedure and treatment efficacy of
PDT are summarized in Table 4. The esophageal sur-
face areas that were treated ranged 2–3 cm2 in level 1,
2–4 cm2 in level 2, 1–2 cm2 in level 3, respectively. The
total irradiation dose ranged 100–150 J in level 1, 150–
300 J in level 2, and 100–200 J in level 3, respectively. A
CR was achieved in 5 of 9 patients (55.6%, 95% Confi-
dence interval [CI]: 21.2–86.3). The CR rate of each flu-
ence level was 33.3% (1/3) in level 1, 66.7% (2/3) in level
2, and 66.7% (2/3) in level 3, respectively. Total 2 of 9
patients irradiated with another session on the next day.
One was at the level 1 (patient No.3), and the other was
at level 3 (patient No.8). Patient No.3 could be achieved
CR, whereas No.8 could not be. There was no severe
toxicity with additional irradiation on the next day.
The median period between PDT and the confirmation
of CR at primary site was 39 days (range: 29–99). A rep-
resentative case of a patient who achieved CR is shown
in Figure 1. Furthermore, the CR rate of patients with
T1 local failure was 66.7% (4/6), and that of patients
with T2 local failure was33.3% (1/3). At the median fol-
low up period of 275 days (range: 91–371), of the
5 patients who achieved CR with PDT, local recurrence
was detected in 2, and the lymph node metastasis was
detected in one patient.
Discussion
In this study, we evaluated for the first time the efficacy
and safety of PDT using talaporfin sodium and diode
laser for patients with ESCC as well as for salvage treat-
ment for the local failure after CRT or RT. We did not
experience any DLT at any levels of laser irradiation and
also had a promising CR rate, therefore PDT using tala-
porfin sodium and diode laser for esophageal cancer
could be a tolerable therapeutic option.
In the present study, skin photosensitivity did not de-
velop in any patients with 2 weeks of sun shade period.
As for other adverse events, we experienced one patient
(11%) in fever, 3 (33%) in esophageal pain, and 1 (11%)
in dysphagia. However, these toxicities were grade 1. In
contrast, in a prior phase II study of PDT using porfimer
sodium and excimer dye laser, approximately 32% of the
patients experienced photosensitivity in spite of 4 to
6 week sun shade period. Furthermore, we observed
esophageal pain (61%), pharyngolaryngeal pain (17%),
dysphagia (39%), and fever (48%) [9]. These toxicities
were grade 1 or 2. These results indicated that talaporfin
-based PDT had merits of less skin photosensitivity and
a shorter sun shade period. However, because the
esophageal surface area irradiated (1–4 cm2 vs 3–9 cm2)


















Level 1 (50 J/cm2)
No.1 60 cisplatin + 5FU residue 1 positive 2.0 <1/4 T2N0M0
No.2 60 nedaplatin + 5FU recurrence 1 positive 1.0 <1/4 T1N0M0
No.3 60 5FU residue 1 negative 1.5 <1/4 T2N0M0
Level 2 (75 J/cm2)
No.4 60 cisplatin + 5FU recurrence 1 positive 1.0 <1/4 T1N0M0
No.5 60 - recurrence 1 positive 0.8 <1/4 T1N0M0
No.6 60 - recurrence 1 positive 2.0 1/4-1/2 T1N0M0
Level 3 (100 J/cm2)
No.7 60 cisplatin + 5FU recurrence 1 positive 1.0 1/4-1/2 T1N0M0
No.8 50.4 cisplatin + 5FU recurrence 1 positive 3.0 <1/4 T2N0M0
No.9 70 cisplatin + 5FU recurrence 1 positive 1.0 <1/4 T1N0M0
Yano et al. Radiation Oncology 2012, 7:113 Page 5 of 7
http://www.ro-journal.com/content/7/1/113and the total laser irradiation dose (100–300 J vs 225–
675 J) were quite different between each study, the tox-
icity related with laser irradiation should be evaluated in
the next phase II study.
While this study was a phase I study, 5 of 9 patients
(55.6%) achieved a CR. The CR rate for the T1 residual
tumors was 66.7%, and that of T2 was 33.3%. These data
were similar to the efficacy with PDT using porfimer
sodium with excimer dye laser. This indicated that
PDT had a high potential for local control for ESCC.
Although further evaluation for the efficacy of talaporfin-
based PDT is necessary in the next step with larger sub-
jects, talaporfin-based PDT demonstrated promising
anti-tumor effect for the ESCC.
Second-line systemic chemotherapy is also a treat-
ment option for patients with treatment failure after
CRT for ESCC. However, systemic chemotherapy hasTable 3 Hematological and non-hematological toxicity
Level 1(50 J/cm2), n = 3 Level 2(75 J/c
Grade Grade
1 2 3 4 1 2
Anemia 0 0 0 0 0 0
White bloode cell decreased 0 0 0 0 0 0
Neutrophil count decreased 0 0 0 0 0 0
Platelet count decreased 0 0 0 0 0 0
Fever 0 0 0 0 1 0
Esophageal pain 1 0 0 0 2 0
Pharyngolaryngeal pain 0 0 0 0 0 0
Dysphagia 1 0 0 0 0 0
Anorexia 0 0 0 0 0 0
Nausea 0 0 0 0 0 0
Photosensitivity 0 0 0 0 0 0not demonstrated a sufficient effect in studies; the over-
all response rate ranged 0%–16%, and the complete
response rate ranged 0%–6% [16-19]. Even for the pri-
mary site, it is quite difficult to achieve CR. This sug-
gests that second-line systemic chemotherapy is most
likely a palliative treatment option. Taken together, sal-
vage PDT could be a curative treatment option for local
failure after CRT.
For treatment failure after CRT for ESCC, salvage sur-
gery is generally indicated. However, it demonstrated a
high rate of complications and treatment-related mortal-
ity ranging from 8% to 22% [2-5]. Therefore, the indica-
tions for salvage surgery should be carefully considered.
In this study, there were no severe adverse events related
to talaporfin sodium-based PDT. Although there was
one case of treatment related death in the prior phase II
study of PDT using porfimer sodium, the rate ofm2), n = 3 Level 3(100 J/cm2), n = 3 Total (any grade, %)
Grade
3 4 1 2 3 4
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 1(11%)
0 0 0 0 0 0 3(33%)
0 0 0 0 0 0 0
0 0 0 0 0 0 1(11%)
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0














Level 1 (50 J/cm2)
No.1 3 150 nonCR - - -
No.2 2 100 nonCR - - -
No.3 3 150 CR 99 No No
Level 2 (75 J/cm2)
No.4 2 150 nonCR - - -
No.5 2 150 CR 63 No Yes (LN)
No.6 4 300 CR 29 No No
Level 3 (100 J/cm2)
No.7 1 100 CR 39 Yes No
No.8 2 200 nonCR - - -
No.9 1 100 CR 33 Yes No
CR complete response, LN lymph node.
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based on these results, that salvage PDT is a less life-
threating treatment option than salvage surgery.
Before starting this study, we performed a pre-clinical
study of PDT using talaporfin sodium and diode laser
for canine esophagus [11]. In that pre-clinical study,
laser irradiation was escalated with three levels of flu-
ence 25, 50, 100 J/cm2 after administration of talaporfin
sodium for three dogs at each levels, and pathologically
evaluated one week after irradiation. The ulceration and
ischemic changes around the ulcer became more severe
as the dose of laser irradiation increased. Pathologically,Figure 1 A patient who achieved complete response with photodyna
detected after chemoradiotherapy. c: during PD laser irradiation. d: two da
e: two weeks after PDT, deep ulceration was observed at the laser irradiatethese changes were confined to the mucosa after irradi-
ation at 25 J/cm2, whereas they appeared as necrosis in
the muscle layer after irradiation at 50 J/cm2, and the
necrosis extended to the extra-adventitial tissue after ir-
radiation at 100 J/cm2. Therefore, we concluded that
25 J/cm2 was within the safe range in normal canine
esophagus. However, this dosage cannot directly apply
for human, because the thickness is different between
human and dog esophagus. Previous data on the normal
canine bronchi and a clinical study of human lung can-
cer suggest that similar effects should be expected in
humans after double-irradiation doses that were used inmic therapy. a: before chemoradiotherapy. b: local residue was
ys after PDT, ischemic change was observed at the laser irradiated site.
d site. f: CR was achieved 10 weeks after PD.
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trials in the esophagus should start with an irradiation
dose of 50 J/cm2, and it might be appropriated from the
safety profile of present study. In conclusion, PDT using
talaporfin sodium and diode laser irradiation demon-
strated an acceptable safety profile with manageable ad-
verse events and promising efficacy for local failure after
RT for patients with esophageal cancer. From the results
of this study, 100 J/cm2 was selected as a recommended
fluence for the next phase II study.
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